Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

DSC Investment

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 60
Average round size
The average size of a deal this fund participated in
Portfolio companies 43
Rounds per year 5.45
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 2
Key employees Soon
Stages of investment

Areas of investment

  • Biotechnology
  • Software
  • Artificial Intelligence
  • Machine Learning
  • Health Care

The main department of described VC is located in the Seoul. The company was established in Asia in South Korea.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the DSC Investment, startups are often financed by Kakao Ventures, Naver Corporation, Korea Investment Partners. The meaningful sponsors for the fund in investment in the same round are Capstone Partners Co., Ltd., Mirae Asset Venture Investment, Korea Investment Partners. In the next rounds fund is usually obtained by Korea Investment Partners, Stonebridge Capital, Mirae Asset Venture Investment.

For fund there is a match between the location of its establishment and the land of its numerous investments - South Korea. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight ABL Bio, LetinAR Co., Ltd., Dable. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most successful fund investment fields, there are Artificial Intelligence, Software.

The fund is constantly included in 2-6 deals per year. Deals in the range of 5 - 10 millions dollars are the general things for fund. Opposing the other organizations, this DSC Investment works on 22 percentage points less the average amount of lead investments. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2018.

Read more

Funds with similar focus

Funds from South Korea
Funds with similar focus located in South Korea:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Health Care
Information Technology
$3M04 Nov 2022 Durham, North Carolina, United States


Air Transportation
$8M17 Oct 2022 Seongnam, Kyonggi-do, South Korea

PineTree Therapeutics

$23M07 Jun 2022 Cambridge, Massachusetts, United States


Fuel Cell
Renewable Energy
$14M10 May 2022 Wilmington, Delaware, United States

Genome Insight

$23M30 Apr 2022 La Jolla, California, United States


Health Care
$17M28 Apr 2022 Seongnam, Kyonggi-do, South Korea


Environmental Engineering
$10M20 Dec 2021 South Korea, Gyeonggi-do, South Korea


Financial Services
$60M15 Dec 2021 Seoul, Seoul-t'ukpyolsi, South Korea


$2M16 Nov 2021 -
PharmCADD Raised USD 16m in Series B Funding

– PharmCADD announced that it has finished USD 16m series B funding on March 31, 2021.
– This funding round was led by Strategic Investors: Huons, Samyang Holdings and SD BIOSENSOR; and Financial Investors: KTB Network, Daily Partners, DSC Investment, KDB Capital, Maple Investment and KB Securities.
– As a result, PharmCADD has secured total of USD 22m in funding since its establishment.
– PharmCADD plans to use the funding not only to launch the U.S. and India-based branches but also to advance its AI & Physics-based drug discovery platform technology, Pharmulator™, and to expand R&D manpower. The funding will be used for the preclinical study of internal pipelines as well.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent DSC Investment?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: